This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Carlo Colosimo, MD; Alberto Albanese, MD; Andrew J. Hughes, FRACP; Veralice M. S. de Bruin, MD; Andrew J. Lees, FRCP

Arch Neurol. 1995;52(3):294-298.

Abstract
Objective
The clinical recognition of multiple system atrophy (MSA) in patients presenting with parkinsonian signs is difficult. We attempted to verify the predictive value of some pointers that are used in clinical practice.

Design
Sixteen consecutive patients with pathologically confirmed MSA who presented with a parkinsonian syndrome over an 8-year period were studied retrospectively, and their clinical features were analyzed in detail.

Setting
Parkinson's Disease Society, Brain Tissue Bank, Institute of Neurology, London, England.

Patients
Sixteen patients with pathologically proven MSA who presented with parkinsonian syndrome in the first 3 years since disease onset.

Methods
Clinical features that were analyzed included the rapidity of disease progression, the relative symmetry of symptom onset, the presence or absence of tremor at initial presentation, the therapeutic response to levodopa and the associated presence of autonomic dysfunction. Fourteen of the 16 patients also had a computed tomographic scan of the brain performed. The frequency of selected items in MSA was compared with that found in 20 pathologically confirmed cases of Parkinson's disease and 16 pathologically confirmed cases of progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Results
It was found that a probability scale based on five selected items discriminated MSA with a pure parkinsonian presentation from Parkinson's disease, but not from progressive supranuclear palsy. Patients affected by the latter disorder, however, commonly presented with additional clinical features (supranuclear vertical down-gaze palsy, axial dystonia, and cognitive impairment), which helped to differentiate it from MSA.

Author Affiliations
From the Department of Neurology, The Middlesex Hospital (Drs Colosimo, Hughes, and Lees), and the Parkinson's Disease Society, Brain Tissue Bank, Institute of Neurology (Drs Colosimo, Hughes, de Bruin, and Lees), London, England; and the Istituto di Neurologia, Università Cattolica, Rome, Italy (Drs Colosimo and Albanese).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Characteristics of orthostatic hypotension in Parkinson's disease
Oka et al.
Brain 2007;0:awm174v1-8.
ABSTRACT | FULL TEXT  

Reproducibility of a Standardized Quantitative Analysis Using Fixed Regions of Interest to Differentiate Movement Disorders on 123I-FP-CIT SPECT
Stokkel et al.
J. Nucl. Med. Technol. 2007;35:21-26.
ABSTRACT | FULL TEXT  

Growth Hormone Stimulation Tests in the Differential Diagnosis of Parkinson's Disease
Pellecchia et al.
Clin Med Res 2006;4:322-325.
ABSTRACT | FULL TEXT  

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Suchowersky et al.
Neurology 2006;66:968-975.
ABSTRACT | FULL TEXT  

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
Lewis et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:343-348.
ABSTRACT | FULL TEXT  

Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease
Riley and Chelimsky
J. Neurol. Neurosurg. Psychiatry 2003;74:56-60.
ABSTRACT | FULL TEXT  

Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?
Osaki et al.
Neurology 2002;59:1486-1491.
ABSTRACT | FULL TEXT  

Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging
Ghaemi et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:517-523.
ABSTRACT | FULL TEXT  

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Hughes et al.
Brain 2002;125:861-870.
ABSTRACT | FULL TEXT  

Increased Growth Hormone Response to Apomorphine in Parkinson Disease Compared With Multiple System Atrophy
Friess et al.
Arch Neurol 2001;58:241-246.
ABSTRACT | FULL TEXT  

Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy
Gilman et al.
Neurology 2000;55:527-532.
ABSTRACT | FULL TEXT  

Progressive supranuclear palsy
Rehman
Postgrad. Med. J. 2000;76:333-336.
ABSTRACT | FULL TEXT  

What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
Wenning et al.
J. Neurol. Neurosurg. Psychiatry 2000;68:434-440.
ABSTRACT | FULL TEXT  

Diagnostic Criteria for Parkinson Disease
Gelb et al.
Arch Neurol 1999;56:33-39.
ABSTRACT | FULL TEXT  

Presymptomatic Hypertension in Progressive Supranuclear Palsy
Fabbrini et al.
Arch Neurol 1998;55:1153-1155.
FULL TEXT  

What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy? A Clinicopathologic Study
Litvan et al.
Arch Neurol 1997;54:937-944.
ABSTRACT  

Autonomic Disorders and Their Recognition
Mathias
NEJM 1997;336:721-724.
FULL TEXT  

Psychological Factors and Pet Measured Glucose Metabolism in Olivopontocerebellar Atrophy
Berent et al.
Assessment 1996;3:339-349.
ABSTRACT  

Multiple System Atrophy
Caraceni et al.
Arch Neurol 1996;53:212-212.
ABSTRACT  

Multiple System Atrophy-Reply
Albanese et al.
Arch Neurol 1996;53:212-213.
ABSTRACT  

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Suchowersky et al.
Neurology 2006;66:968-975.
ABSTRACT | FULL TEXT